37

37 Publications Verification

Synonyms: MK-3475; Lambrolizumab

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

STM3006

3 Cited Publications

Cat. No.: HY-156773

CAS No.: 2499664-52-5

Purity: 98.71%

Target:

Apoptosis METTL3

Research Areas:

Cancer

STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC₅₀: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

MYCi361

3 Cited Publications

Cat. No.: HY-129600

CAS No.: 2289690-31-7

Purity: 99.95%

Synonyms: NUCC-0196361

Target:

c-Myc

Research Areas:

Cancer

MYCi361 (NUCC-0196361) is a MYC inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Laminaran

2 Cited Publications

Cat. No.: HY-119109

CAS No.: 9008-22-4

Purity: ≥98.0%

Category:

Polysaccharides Microorganisms Plants Other Families Extract Disease Research Fields Saccharides Cancer

Target:

Environmental Pollutants Endogenous Metabolite C-type Lectin-like Receptors (CTLRs)

Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities . Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds . Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

680C91

2 Cited Publications

Cat. No.: HY-108681

CAS No.: 163239-22-3

Purity: 99.54%

Target:

Collagen

Research Areas:

Neurological Disease Inflammation/Immunology Cancer

680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a K_i of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

EP4 receptor antagonist 1

2 Cited Publications

Cat. No.: HY-133123

CAS No.: 2287259-07-6

Purity: 99.66%

Target:

Prostaglandin Receptor

Research Areas:

Inflammation/Immunology Cancer

EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC₅₀s of 6.1 nM and 16.2 nM, respectively. IC₅₀s >10 μM for human EP1, EP2,and EP3 receptors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

METTL1-WDR4-IN-1

2 Cited Publications

Cat. No.: HY-162080

CAS No.: 374705-10-9

Target:

DNA Methyltransferase Pyruvate Kinase

Research Areas:

Cancer

METTL1-WDR4-IN-1 (Compound 1) is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC₅₀ = 144 μM). METTL1-WDR4-IN-1 inhibits the m ⁷G methyltransferase activity of the METTL1-WDR4 complex, blocking m ⁷G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 ⁺ T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

METTL1-WDR4-IN-1 TFA

2 Cited Publications

Cat. No.: HY-162080A

Target:

DNA Methyltransferase Pyruvate Kinase

Research Areas:

Cancer

METTL1-WDR4-IN-1 (Compound 1) TFA is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC₅₀=144 μM). METTL1-WDR4-IN-1 TFA inhibits the m ⁷G methyltransferase activity of the METTL1-WDR4 complex, blocking the m ⁷G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 TFA can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 ⁺ T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 TFA can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

TL8-506

1 Cited Publications

Cat. No.: HY-20457

CAS No.: 1268163-15-0

Target:

Toll-like Receptor (TLR) Bacterial Interleukin Related

Research Areas:

Inflammation/Immunology Cancer

TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Serpin B9-IN-1

1 Cited Publications

Cat. No.: HY-33299

CAS No.: 154235-77-5

Synonyms: BTCA

Target:

Biochemical Assay Reagents

Research Areas:

Cancer

Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

EGFRvIII peptide (PEPvIII) TFA

1 Cited Publications

Cat. No.: HY-P1828A

Target:

EGFR

Research Areas:

Cancer

EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

Compare

loading...